Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Carvelli, Julien; Demaria, Olivier; Vély, Frédéric; Batista, Luciana; Benmansour, Nassima Chouaki; Fares, Joanna; Carpentier, Sabrina; Thibult, Marie-Laure; Morel, Ariane; Remark, Romain; André, Pascale; Represa, Agnès; Piperoglou, Christelle; Cordier, Pierre Yves; Le Dault, Erwan; Guervilly, Christophe; Simeone, Pierre; Gainnier, Marc; Morel, Yannis; Ebbo, Mikael; Schleinitz, Nicolas; Vivier, Eric

Coronavirus disease 2019 (COVID-19) is a new pandemic disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The C5a anaphylatoxin and its receptor C5aR1 (CD88) play a key role in the initiation and maintenance of several inflammatory responses, by recruiting and activating neutrophils and monocytes in the lungs(1). We provide a longitudinal analysis of immune responses, including immune cell phenotyping and assessments of the soluble factors present in the blood and broncho-alveolar lavage fluid (BALF) of patients at various stages of COVID-19 severity: paucisymptomatic, pneumonia and acute respiratory distress syndrome (ARDS). We report an increase in soluble C5a levels proportional to COVID-19 severity and high levels of C5aR1 expression in blood and pulmonary myeloid cells, supporting a role for the C5a-C5aR1 axis in the pathophysiology of ARDS. Anti-C5aR1 therapeutic monoclonal antibodies (mAbs) prevented C5a-mediated human myeloid cell recruitment and activation, and inhibited acute lung injury (ALI) in human C5aR1 knockin mice. These results suggest that C5a-C5aR1 axis blockade might be used as a means of limiting myeloid cell infiltration in damaged organs and preventing the excessive lung inflammation and endothelialitis associated with ARDS in COVID-19 patients.